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Abstract
Our previous data illustrated that activation of the canonical Wnt signaling pathway was en-
riched in triple-negative breast cancer and associated with reduced overall survival in all pa-
tients. To determine whether Wnt signaling may be a promising therapeutic target for triple-
negative breast cancer, we investigated whether β-catenin was necessary for tumorigenic be-
haviors in vivo and in vitro. β-catenin expression level was significantly reduced in two human
triple-negative breast cancer cell lines, MDA-MB-231 and HCC38, using lentiviral delivery of
β-catenin-specific small hairpin RNAs (shRNAs). Upon implantation of the cells in the mam-
mary fat pad of immunocompromised mice, we found that β-catenin shRNA HCC38 cells
formed markedly smaller tumors than control cells and grewmuchmore slowly. In in vitro as-
says, β-catenin silencing significantly reduced the percentage of Aldefluor-positive cells, a
read-out of the stem-like cell population, as well as the expression of stem cell-related target
genes including Bmi-1 and c-Myc. β-catenin-knockdown cells were also significantly im-
paired in their ability to migrate in wound-filling assays and form anchorage-independent colo-
nies in soft agar. β-catenin-knockdown cells were more sensitive to chemotherapeutic agents
doxorubicin and cisplatin. Collectively, these data suggest that β-catenin is required for triple-
negative breast cancer development by controlling numerous tumor-associated properties,
such as migration, stemness, anchorage-independent growth and chemosensitivity.
Introduction
Triple-negative breast cancer (TNBC), including basal-like breast tumors, is an aggressive
tumor subtype that is distinguished from other breast cancer subtypes by its gene expression
profiles, histopathological features, and clinical characteristics [1–3]. These tumors can be par-
ticularly challenging clinically because, although these tumors respond well to chemotherapy
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at least initially, they often develop drug resistance [4]. By virtue of TNBC lacking estrogen re-
ceptor (ER), progesterone receptor (PR) and HER2 expression, there are no targeted biological
therapies currently used as standard treatment for these cancers [1, 5]. Therefore, an important
goal of research in the TNBC field is to identify those signaling pathways that drive tumor be-
havior and may also serve as potential therapeutic targets.
The canonical Wnt signal transduction pathway is activated in several tumor types, includ-
ing colorectal and breast cancer [6–8]. Among other mechanisms, the major effector of the ca-
nonical Wnt pathway, β-catenin, is stabilized in tumors primarily via Wnt ligand
overexpression, down-regulation of Wnt ligand antagonists, or loss of the APC tumor suppres-
sor [9]. As a consequence of its stabilization, β-catenin translocates to the nucleus where it con-
trols gene expression through its association with members of the T cell factor (TCF) family of
transcription factors. Some of the β-catenin/TCF transcriptional targets implicated in tumor
initiation and progression include the cell cycle regulators cyclin D1 [10] and c-Myc [11], stem
cell gene Bmi-1 [12], matrix metalloproteinaseMmp-7 [13], and Wnt pathway component
Axin2 [14]. Our laboratory and others have demonstrated that the Wnt pathway is more fre-
quently activated in TNBC than in other breast cancer subtypes (e.g., ER-positive cancers)
[15–17]. Moreover, nuclear and cytosolic accumulation of β-catenin, but not membrane-
associated β-catenin, is associated with reduced overall survival in all breast cancer patients
[16]. We sought to determine the impact of Wnt/β-catenin pathway activation on the malig-
nant and metastatic potential of TNBC cells in vitro and in vivo. In the present study, our
group analyzed the role of β-catenin in the tumorigenic properties of TNBC cell lines to ad-
dress its potential utility as a therapeutic target in this tumor type.
Materials and Methods
Ethics Statement
All procedures were performed with prior approval (protocol #71828) from the University of
Chicago Institutional Animal Care and Use Committee, which has full accreditation from the
Association for Assessment and Accreditation of Laboratory Animal Care.
Cell lines and β-catenin knockdown
MDA-MB-231 and HCC38 cell lines were from ATCC and cultured in RPMI 1640 media
(Invitrogen, Grand Island, NY) supplemented with 10% FBS and 1% penicillin/streptomycin.
The stable knock down lines of MDA-MB-231 and HCC38 were established by infection of
MISSION shRNA Lentiviral Transduction Particles against CTNNB1 (Sigma-Aldrich,
TRCN0000003845 and TRCN0000003846) and selected with puromycin (1ug/ml).
Western blotting
Total cell lysates were extracted with 50 mM Tris pH7.5, 0.1% IGEPAL, 100 mMNaCl, 1 mM
MgCl2, 5 mM EDTA and protease inhibitors and sonicated. 25 µg of lysate from each cell line
was separated on a 10% SDS-PAGE gel and transferred to Immobilon P membrane (Millipore).
Blots were probed with 1:1000 anti-β-catenin monoclonal antibody (BD Biosciences), 1:1000
anti-active (unphosphorylated) β-catenin (EMDMillipore) and 1:1000 anti-actin monoclonal
antibody (Sigma) in blocking buffer (5% nonfat dried milk in TBST).
TOPFlash reporter assays
Cells were plated in a 24-well plate at a density of 1x104 cells/well and transfected using Opti-
fect (Invitrogen) with 2.6 μg of pTOPflash or pFOPflash (obtained from H. Clevers at the
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Hubrecht Insitute) along with pRL-TK (Promega) for determination of transfection efficiency.
Lysates were harvested after 48 hrs and analyzed using the Dual Luciferase Assay System kit
(Promega). Luciferase activity was normalized for transfection efficiency and graphed as ratio
of TOPflash/FOPflash activity. Mutant β-cateninS37A was from Stephen Byers at Georgetown
University. The breast cancer lines were transfected with stabilized mutant β-cateninS37A as de-
scribed previously [18]. Expression was verified by GFP fluorescence and Western blotting
with a HA antibody (Santa Cruz).
Cell growth, migration and soft agar growth assays
Cell growth was analyzed with MTS assay using CellTiter 96 AQueous One Solution Cell Pro-
liferation Assay (Promega, WI) following the protocol. Cells were seeded in 96-well culture
plates at a density of 5×103 cells/well. Cell viability was assessed by adding
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium
(MTS) to the culture medium and incubated for 4 h at 37 °C. The optical density was measured
at 490 nm using Synergy 2 plate reader (Biotek, VT). Cell migration was measured by wound
healing assays as described [18]. Briefly, cells were plated at a density of 1 x 105 cells per well in
a 6-well plate were grown to confluence, at which time they were scratched with a micropipette
tip. Phase-contrast images were captured with a Zeiss Axiovert 35 inverted microscope using
AxioVision REL 4.6 imaging software (Zeiss) every 12 hr. The area of three representative
wounds for each cell line was quantified at each time point using Image J software (NIH). An-
chorage-independent growth soft agar assays were performed by seeding 4 x 103 cells in 0.3%
agarose as described [19]. The colonies were quantified at day 14 from five fields in
triplicate wells.
Stem cell assays
ALDEFLOUR assays (Stemcell) were used. 5x105 cells were stained with ALDEFLOUR reagent
or ALDEFLOUR reagent plus ALDEFLOUR inhibitor. Stained cells were sorted by the Univer-
sity of Chicago Flow Cytometry Core Facility.
Quantitative real-time PCR
Gene expression changes were analyzed by real-time RT-PCR as described [20] except ribo-
somal RNA 18S was used as a normalization control. The primer sequences for c-Myc: Forward
5’-CAG CTG CTT AGA CGC TGG ATT T-3’; Reverse 5’-ACC GAG TCG TAG TCG AGG
TCA T-3’.The primer sequences for Axin2: Forward 5’-CTG GCT TTG GTG AAC TGT TG-
3’; Reverse 5’- AGT TGC TCA CAG CCA AGA CA-3’. The primer sequences for Bmi-1: For-
ward 5’-CTC CCA ACT GGT TCG ACC TT-3’; Reverse 5’-CGG TTT CCA TAT TTC TCA
GT-3’. The primer sequences for ribosomal RNA 18S has been reported [18]. The fold change
in target gene relative to the control was determined by 2-ΔΔCt method.
Xenograft transplantation assays
5 x 106 parental, scrambled control shRNA or β-catenin-knockdown cells were injected with
Matrigel (BD Biosciences) into the mammary fat pad of Nu/Nu female mice (n = 10 per
group). Tumors were measured biweekly with calipers after implantation, and the animals
were sacrificed 11 weeks later. Tumor volume was calculated as described previously [8]. After
euthanasia, tumors were fixed, sectioned and stained with hematoxylin and eosin (H&E); im-
ages were captured on a Leica DMLB microscope using Qcapture Pro 6.0 imaging software.
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Therapeutic response of TNBC cells
β-catenin-knockdown and control HCC38 cells were treated with 0.5 μM doxorubicin or 3.0
μM cisplatin for 24 hrs and subjected to an Caspase 3/7 Glo assay (Promega, WI, USA). Rela-
tive sensitivity was shown as β-catenin-knockdown over control.
Statistical analysis
All experiments were performed at least in triplicate, and statistical significance was defined as
a p value of<0.05 using a one-way ANOVA with a Student’s t-test post-test, unless noted oth-
erwise. For quantification, means are shown with standard deviation (SD).
Results
In order to identify in vitromodels of TNBC that recapitulate some of the features of human
tumors with respect to Wnt signaling, several breast cancer cell lines were analyzed for total
and “activated”, or non-phosphorylated, β-catenin by Western blotting. Total and “activated”
β-catenin were expressed at high levels in HCC1937, UACC3199 and HCC38 TNBC cell lines
compared to the ER-positive MCF-7 and another TNBC line MDA-MB-231 (Fig. 1A). Inter-
estingly, despite the high levels of “activated” β-catenin, none of the cell lines demonstrated sig-
nificant basal TCF reporter activity (Fig. 1B). However, reporter activity was induced in most
of the cell lines upon transient overexpression of a stabilized S37A mutant of β-catenin
(Fig. 1C). There was significant variability among the cell lines in the extent of pathway activa-
tion in response to stabilized β-catenin overexpression, suggesting that there are other factors,
beyond the levels of exogenous or endogenous β-catenin, that contribute to β-catenin/TCF
transcriptional activity. Two TNBC cell lines with similar levels of induced TCF reporter activi-
ty, MDA-MB-231 and HCC38, were selected to test the function of β-catenin using RNA inter-
ference. β-catenin expression was stably knocked down in each cell line by lentiviral
transduction of β-catenin-specific shRNA and selection with puromycin. Scrambled shRNA
was used as control. Western blotting with anti-β-catenin antibodies illustrated that there was
a significant reduction in β-catenin levels in the stable β-catenin shRNA cell lines compared to
controls (Fig. 1D).
The impact of β-catenin knockdown on several in vitro biological properties associated with
TNBC tumorigenesis was assessed. To address tumor cell migration, β-catenin shRNA and
control TNBC cells were subjected to wound filling assays. Stable knockdown of β-catenin sig-
nificantly suppressed migration of both MDA-MB-231 and HCC38 cells compared to that of
control cells (Fig. 2). The effect was more pronounced in the HCC38 cells. Since the HCC38
has higher level of β-catenin and showed more dramatic phenotypic differences upon β-catenin
knockdown, we chose HCC38 cells for further analysis. The stem-like cell population was
quantified in β-catenin-knockdown and control HCC38 cells using an ALDEFLUOR assay and
flow cytometry. As shown in a representative plot and in the graph of means from two experi-
ments in Fig. 3A and 3B, control HCC38 cells had approximately 30% ALDEFLUOR-positive
cells, while β-catenin-knockdown cells had fewer than 5% ALDEFLUOR-positive cells. Consis-
tent with this finding, the expression of β-catenin/TCF target gene, and stemness regulator,
Bmi-1, was significantly lower in β-catenin-knockdown cells compared to control cells. Other
β-catenin/TCF targets, including Axin2 and c-Myc, were similarly downregulated in β-catenin-
knockdown cells, although levels of the target Tert was not significantly changed (Fig. 3C).
Lastly, similar to migration and stemness, colony formation in soft agar was significantly re-
duced in β-catenin-knockdown HCC38 cells compared to control cells (Fig. 3D). Collectively,
these data indicate that β-catenin activity is required for many of the tumorigenic
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characteristics of TNBC cells, including cell migration, stem-like cell properties and colony for-
mation. Notably, proliferation was unchanged in β-catenin-knockdown cells (S1 Fig.).
We next tested the requirement for β-catenin in the in vivo tumorigenic potential of HCC38
TNBC cells upon orthotopic transplantation (n = 10 per group). As shown in Fig. 4A and 4B,
the average tumor volume and growth were significantly decreased for cells with β-catenin
knockdown compared to parental and control shRNA cells. The tumors that formed in mice
injected with β-catenin-knockdown cells were very small and necrotic (Fig. 4C). These data in-
dicate that β-catenin is necessary for TNBC initiation and growth in vivo.
Finally, the impact of Wnt/β-catenin signaling on the chemotherapeutic response of TNBC
cells was investigated. Specifically, the sensitivity of β-catenin-knockdown cells was compared
to that of control cells each treated with 0.5 μM doxorubicin or 3.0 μM cisplatin, and we found
Figure 1. β-catenin is overexpressed in TNBC cell lines. (A) Western blots of total lysates were probed with antibodies against total β-catenin and
active β-catenin (EMDMillipore). (B) Basal TCF reporter activity was measured upon transfection with pTOPFlash or pFOPFlash for 48 hr. Normalized
luminescence values are presented as TOP/FOP ratio. (C) TCF reporter activity of the cells was measured upon transient transfection of mutant
β-cateninS37A. Values were normalized to vector-transfected cells. (D) β-catenin expression was stably knocked down in MDA-MB-231 and HCC38 cells by
lentiviral transduction of CTNNB1-specific or scrambled control shRNAs, andWestern blotting was performed as in A.
doi:10.1371/journal.pone.0117097.g001
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that the β-catenin-knockdown cells were more sensitive to doxorubicin or cisplatin-
induced cell death after 24-hour treatment compared to control shRNA cells (Fig. 5). The effect
was more profound with doxorubicin treatment compared to cisplatin treatment. It suggests
that β-catenin/TCF-mediated gene regulation is important for the chemosensitivity of
TNBC cells.
Discussion
We have previously shown that β-catenin-dependent Wnt signaling is enriched in TNBCs and
is associated with reduced overall survival in breast cancer patients [16]. In the present study,
we tested the requirement for β-catenin andWnt signaling in the tumorigenic potential of
human TNBC cell lines. We found that β-catenin is necessary for TNBC cell migration, colony
formation and stem cell properties in vitro and tumorigenesis in immunocompromised mice.
In addition, the responsiveness of TNBC cells to chemotherapeutic agents, such as doxorubicin
and cisplatin, is dependent on β-catenin andWnt pathway status.
Figure 2. Stable knockdown of β-catenin suppresses migration of triple-negative breast cancer cells. Confluent monolayers of β-catenin-knockdown
or control MDA-MB-231 (A-B) and HCC38 (C-D) cells were scratched with a micropipette tip and imaged up to 5 days after on an inverted microscope every
12 hr. Quantification was performed on two separate experiments performed in triplicate. Wound area was quantified with Image J software. *p<0.01.
doi:10.1371/journal.pone.0117097.g002
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It has been reported that β-catenin signaling dosage dictates tissue-specific tumor predispo-
sition in Apc-driven cancer. In a mouse model, Apc1638N, with reduced β-catenin levels, fe-
male mice developed mammary tumors instead of gastrointestinal tumors [21]. We found that
the dosage of β-catenin was important in downstream target gene regulation and affected sev-
eral behaviors associated with tumorigenesis and development of TNBC. In stable β-catenin
knock-down TNBC cells, reduction of β-catenin levesl did not affect cell growth; yet, other phe-
notypes, such as cell migration, were significantly impaired. DiMeo et al. reported that Wnt
signaling was not required for the proliferation of SUM1315 cells in culture as cells overexpres-
sing the Wnt inhibitors SFRP1, DKK1, or shRNA against LRP6, grew at similar rates in vitro
compared with SUM1315 control cells [22]. Consistent with our findings, Matsuda et al. dem-
onstrated that ectopic SFRP1 expression caused a reduction of motility in MDA-MB-231 cells
[23]. Together, these data suggest that the Wnt/β-catenin pathway is crucial for controlling cell
motility, a property that is significantly associated with metastasis and poor prognosis of
TNBC.
Wnt/β-catenin pathway activation has been implicated in stem cell self-renewal, mainte-
nance, and differentiation [22, 24–26]. Many cancers, including breast cancer, contain
Figure 3. β-catenin is required for stemness and the colony formation capacity of HCC38 TNBC cells. (A-B) The stem-like population of β-catenin-
knockdown and control HCC38 cells was measured using the ALDEFLOUR assay (Stemcell) and flow cytometry. Data showmeans ± SD of two
independent experiments. *p<0.01. (C) Gene expression changes in β-catenin-knockdown cells were analyzed by qRT-PCR as described (Xu et al., 2010)
except that ribosomal 18S RNA was used as a normalization control. The fold change in target genes relative to the control was determined by
2-ΔΔCt method. *p<0.05. (D) Soft agar assays were performed by seeding cells in 0.3% agarose and was quantified at day 14 (i.e. five fields from triplicate
wells). Data are means ± SD of three independent experiments. *p< 0.05.
doi:10.1371/journal.pone.0117097.g003
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populations of cells that display stem-like cell properties [9]. In breast cancer, those popula-
tions can be marked as CD44high/CD24low [27] and ALDEFLUOR-positive [28]. We and others
have reported that nuclear and cytosolic accumulation of β-catenin was correlated with high
levels of a CD44high/CD24low stem cell population in primary TNBC/basal-like breast cancers
[16, 29]. In this study, we demonstrated that β-catenin knockdown caused a significant de-
crease in the ALDEFLUOR-positive stem cell population in TNBC cell lines. In addition, stem-
ness regulators, such as Bmi-1 and c-Myc, were down-regulated in β-catenin-knockdown cells
compared to control cells. The epithelial-mesenchymal transition (EMT) promoter and Wnt
target gene Axin2 [14, 30] was also down-regulated. Furthermore, the tumors that formed in
mice injected with β-catenin-knockdown TNBC cells were much smaller compared to parental
and control shRNA cells. These data suggest that β-catenin is required for cancer stem cell
maintenance and EMT features which are also often associated with tumor relapse and metas-
tasis. Thus, targeting β-catenin may have important implications in TNBC therapy since it
may perturb the tumor stem cell population that is more resistant to chemotherapy than the
bulk of the tumor.
Because TNBCs lack treatment targets due to its triple-negative nature, chemotherapy is the
standard treatment. Doxorubicin has been widely used to treat breast cancer especially TNBC
Figure 4. β-catenin knockdown reduces the in vivo tumorigenic potential of HCC38 TNBC cells. (A) 5x106^ parental, scrambled control shRNA or β-
catenin-knockdown cells were injected with matrigel into the mammary fat pad of Nu/Nu female mice (n = 10 per group) and were sacrificed 11 weeks later.
Dot plot of tumor volume for tumor-bearing mice is shown with mean per group demarcated by the line. p<0.04 between β-catenin-knockdown and control
cells by ANOVA. (B) Tumor growth over 11 weeks after implantation and biweekly measurements. p<0.05 between β-catenin-knockdown and control cells
by ANOVA. (C) Histopathology of tumors frommice injected with β-catenin-knockdown and control. Tumors were fixed, sectioned and stained with H&E.
Magnification, 10X.
doi:10.1371/journal.pone.0117097.g004
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[31, 32]. In a neoadjuvant trial, single-agent cisplatin induced response in a subset of patients
with TNBC [33]. We found that the β-catenin-knockdown cells were more sensitive to
doxorubicin- or cisplatin-induced cell death. These findings indicate that transcriptional activi-
ty of β-catenin is important for the chemosensitivity of TNBC cells, and β-catenin may be an
attractive therapeutic target for TNBC. There is considerable interest in developing Wnt/β-
catenin pathway inhibitors as anti-cancer therapeutics [34]. Recently, it has been reported that
treatment of TNBC-derived cell lines and primary mouse tumor cells with small molecule in-
hibitor ICG-001 blocks proliferation in TNBC cells through down-regulating expression of
HMGA2, a regulator of stem cell self-renewal, proliferation and differentiation [35, 36]. We
predict that a combination therapy of chemotherapy drugs and Wnt/β-catenin inhibitors may
be a more effective way to treat TNBC than with a single agent. Collectively, our findings have
significant implications for TNBC patients treated with chemotherapeutics and the develop-
ment of combination cancer therapy.
Supporting Information
S1 Fig. Stable β-catenin-knockdown does not affect cell growth.MDA-MB-231 (A) and
HCC38 (B) cells were seeded in 96-well plates and cell proliferation was measured with MTS
assay for 96 hrs. Bar represents means ± SD.
(TIF)
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